[Remission of metastatic duodenal cancer after treatment with BRAF inhibitor].
Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.